Sight Sciences, Inc. (NASDAQ:SGHT) CTO Sells $12,482.54 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 3,829 shares of the firm’s stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $3.26, for a total transaction of $12,482.54. Following the completion of the sale, the chief technology officer now owns 1,749,541 shares of the company’s stock, valued at approximately $5,703,503.66. This trade represents a 0.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

David Badawi also recently made the following trade(s):

• On Friday, January 3rd, David Badawi sold 3,111 shares of Sight Sciences stock. The shares were sold at an average price of $3.52, for a total value of $10,950.72.

Sight Sciences Trading Up 0.3 %

Shares of SGHT stock opened at $3.32 on Friday. The company has a current ratio of 10.18, a quick ratio of 9.74 and a debt-to-equity ratio of 0.36. Sight Sciences, Inc. has a twelve month low of $3.20 and a twelve month high of $8.45. The company’s 50-day moving average price is $3.86 and its 200-day moving average price is $5.54. The stock has a market cap of $168.51 million, a price-to-earnings ratio of -3.25 and a beta of 2.57.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. The business had revenue of $20.16 million during the quarter, compared to analysts’ expectations of $20.41 million. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. As a group, equities analysts predict that Sight Sciences, Inc. will post -1.01 earnings per share for the current year.

Analyst Ratings Changes

SGHT has been the topic of a number of research analyst reports. Needham & Company LLC restated a “hold” rating on shares of Sight Sciences in a research note on Friday, November 8th. Morgan Stanley decreased their target price on Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a report on Monday, November 11th. Lake Street Capital downgraded Sight Sciences from a “buy” rating to a “hold” rating and lowered their target price for the stock from $10.00 to $5.00 in a research note on Monday, November 4th. Piper Sandler restated a “neutral” rating and issued a $5.50 price target (down previously from $6.00) on shares of Sight Sciences in a research note on Friday, November 8th. Finally, UBS Group assumed coverage on Sight Sciences in a report on Friday, December 6th. They issued a “buy” rating and a $5.50 price target for the company. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, Sight Sciences has a consensus rating of “Hold” and an average target price of $5.12.

Hedge Funds Weigh In On Sight Sciences

Large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp boosted its position in Sight Sciences by 70.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 102,461 shares of the company’s stock valued at $683,000 after buying an additional 42,383 shares during the period. Rhumbline Advisers grew its stake in Sight Sciences by 40.1% during the 2nd quarter. Rhumbline Advisers now owns 40,811 shares of the company’s stock worth $272,000 after purchasing an additional 11,671 shares in the last quarter. Acadian Asset Management LLC raised its position in Sight Sciences by 256.6% in the 2nd quarter. Acadian Asset Management LLC now owns 83,693 shares of the company’s stock valued at $556,000 after purchasing an additional 60,220 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Sight Sciences by 31.1% in the 2nd quarter. American Century Companies Inc. now owns 35,948 shares of the company’s stock valued at $240,000 after buying an additional 8,527 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Sight Sciences during the second quarter worth approximately $95,000. 55.51% of the stock is currently owned by institutional investors and hedge funds.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.